INT24672

Context Info Confidence 0.71 First Reported 1989 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 27 Total Number 27 Disease Relevance 14.59 Pain Relevance 2.48

signal transduction (FGF2) extracellular space (FGF2) extracellular region (FGF2) nucleus (FGF2) cytoplasm (FGF2)

Anatomy Link Frequency fibroblast 3 stem cells 2 macrophages 1 anterior 1 platelets 1 FGF2 (Homo sapiens)

Pain Link Frequency Relevance Heat cytokine 258 100.00 Inflammation 253 100.00 Nerve growth factor 9 100.00 Angina 64 99.72 Osteoarthritis 56 99.64 metalloproteinase 227 99.36 IPN 5 98.28 COX-2 inhibitor 65 96.36 chemokine 81 96.00 cINOD 22 95.36

Disease Link Frequency Relevance Heat INFLAMMATION 300 100.00 Cancer 414 99.88 Cv General 3 Under Development 58 99.72 Frailty 60 99.64 Malignant Neoplastic Disease 27 99.64 Renal Cancer 1 99.60 Atherosclerosis 44 98.96 Metastasis 57 98.06 Eosinophilic Esophagitis 212 97.72 Sarcoma 159 97.40

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Biotinylation of collagen and the growth factors allows immobilization of HBGF2 and EGF by high affinity binding of tetravalent avidin.

Localization (immobilization) of HBGF2

1) Confidence 0.71 Published 1989 Journal J. Surg. Res. Section Abstract Doc Link 2469861 Disease Relevance 0 Pain Relevance 0

Additional migration of monocytes is facilitated by the secretion of several growth factors including VEGF, bFGF and MCP-1 (monocyte chemoattractant protein 1).

Localization (secretion) of bFGF in monocytes

2) Confidence 0.69 Published 2003 Journal J Transl Med Section Body Doc Link PMC239962 Disease Relevance 0.98 Pain Relevance 0.11

FGF-2 rapidly induced activation of ERK1/2 and p38 MAP kinases, and specific inhibitors for these enzymes significantly reduced FGF-2-induced IL-6 release.

Localization (release) of FGF-2

3) Confidence 0.67 Published 2004 Journal Pancreas Section Body Doc Link 15502643 Disease Relevance 0 Pain Relevance 0

Presence of VEGF and bFGF has been demonstrated in atherosclerotic lesions produced mainly by macrophages [22,23].

Localization (Presence) of bFGF in macrophages associated with atherosclerosis

4) Confidence 0.64 Published 2003 Journal J Transl Med Section Body Doc Link PMC239962 Disease Relevance 0.59 Pain Relevance 0.20

In neurally differentiated hADSCs, immunoreactivities for neural stem cell markers (nestin), neuronal markers (Tuj1, MAP2, NFL, NFM, NFH, NSE, and NeuN), synaptic markers (GAP43 and SNAP25), astrocyte marker (GFAP), and oligodendrocyte marker (CNPase) were very high when grown in the presence of bFGF and forskolin supplements (Figure 3a, 3b).

Localization (presence) of bFGF in stem cell

5) Confidence 0.56 Published 2010 Journal BMC Cell Biol Section Body Doc Link PMC2867791 Disease Relevance 0 Pain Relevance 0

300, sc-21735, Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit polyclonals against FGF2 (1?

Localization (polyclonals) of FGF2

6) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793011 Disease Relevance 0.12 Pain Relevance 0

Mast cells can secrete several mediators involved in angiogenesis, such as VEGF, bFGF, TGF?

Localization (secrete) of bFGF in Mast cells

7) Confidence 0.52 Published 2010 Journal Respir Res Section Body Doc Link PMC2955663 Disease Relevance 0.75 Pain Relevance 0.28

In contrast to the findings of others, neither indomethacin nor NS398 affected tumor cell secretion of angiogenic factors (VEGF, bFGF, IL-8) at concentrations that produced maximal inhibition of PGE2 production, and higher concentrations increased angiogenic factor production.

Localization (secretion) of bFGF associated with cancer

8) Confidence 0.45 Published 2004 Journal Cancer Biol. Ther. Section Abstract Doc Link 15477758 Disease Relevance 0.82 Pain Relevance 0.22

Eosinophils are also known to secrete bFGF [23] and FGF-9 [24] upon the presence of necrotic epithelial cells. bFGF is also known to be secreted in case of cellular damage, such as the esophageal epithelial tissue damage experienced by EoE subjects [12].

Localization (secreted) of bFGF in epithelial cells associated with eosinophilic esophagitis

9) Confidence 0.41 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2976489 Disease Relevance 0.77 Pain Relevance 0

Local sustained release of high dose (but not low dose) FGF-2 to ischemic areas, in 24 patients during bypass surgery, led to a reduction in stress defect size [15].

Localization (release) of FGF-2 associated with stress

10) Confidence 0.39 Published 2001 Journal Curr Control Trials Cardiovasc Med Section Body Doc Link PMC64829 Disease Relevance 0.67 Pain Relevance 0.12

Eosinophils are also known to secrete bFGF [23] and FGF-9 [24] upon the presence of necrotic epithelial cells. bFGF is also known to be secreted in case of cellular damage, such as the esophageal epithelial tissue damage experienced by EoE subjects [12].

Localization (secrete) of bFGF in Eosinophils associated with eosinophilic esophagitis

11) Confidence 0.39 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2976489 Disease Relevance 0.77 Pain Relevance 0

Triple medication was neither for FaDu nor for HeLa cells more effective than Celecoxib® alone, pinpointing that COX-2 inhibition was instrumental in the reduction of bFGF release by tumour cells.

Localization (release) of bFGF in FaDu associated with cancer

12) Confidence 0.36 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.59 Pain Relevance 0.04

An excessive increase in the uPA system was shown to associate with tumour progression and metastasis formation [29-31], and an increase in MMPs is associated with degradation of ECM leading to the release of growth factors like bFGF and VEGF.

Localization (release) of bFGF associated with cancer and metastasis

13) Confidence 0.36 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 1.05 Pain Relevance 0.04

At D14, cells were plated on ornithine/laminine coated slides and maintained during 4 weeks or more in the presence of GRM/bFGF.

Localization (presence) of bFGF

14) Confidence 0.35 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2346555 Disease Relevance 0.09 Pain Relevance 0

Treatment of tumour cells with the triple combination of inhibitors not only impacted on bFGF release but also displayed functional effects.

Localization (release) of bFGF associated with cancer

15) Confidence 0.32 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2841144 Disease Relevance 0.52 Pain Relevance 0.05

Malignant plasma cells can secrete various cytokines, including VEGF, basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF), all known for their pro-angiogenic activity [42].

Localization (secrete) of bFGF in HGF associated with malignant neoplastic disease and cytokine

16) Confidence 0.31 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.46 Pain Relevance 0.05

time-dependently, VEGF and bFGF secretion in human renal cell carcinoma cells [66].

Localization (secretion) of bFGF associated with renal cancer

17) Confidence 0.31 Published 2008 Journal PPAR Research Section Body Doc Link PMC2366048 Disease Relevance 0.89 Pain Relevance 0.04

This includes the release of the nerve growth factor (NGF), VEGF and basic fibroblast growth factor (bFGF) and the modulations of neurotrophic and angiogenic factors gene expression [61].

Localization (release) of bFGF in fibroblast associated with nerve growth factor

18) Confidence 0.30 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2956109 Disease Relevance 0.52 Pain Relevance 0.19

Over the time period evaluated, little (i.e. <1%) of the basic fibroblast growth factor (bFGF) loaded into the IPNs evaluated was released, independent of modifications made to the IPN formulation.

Neg (independent) Localization (released) of bFGF in fibroblast associated with ipn

19) Confidence 0.30 Published 2003 Journal Biomaterials Section Abstract Doc Link 12834587 Disease Relevance 0.24 Pain Relevance 0.45

The relatively high proliferation in platelets activated with 10% calcium was likely due to additional release of bFGF and it might partially compensate for the inhibition by the high concentration of calcium.

Localization (release) of bFGF in platelets

20) Confidence 0.24 Published 2010 Journal The Journal of Advanced Prosthodontics Section Body Doc Link PMC2984511 Disease Relevance 0.06 Pain Relevance 0.03

General Comments

This test has worked.